Debiopharm Competitors and Similar CompaniesClear all

Debiopharm's competitors and similar companies include TriSalus Life Sciences, Sunshine Biopharma, Turning Point Therapeutics and Pyxis Oncology.
Debiopharm
Debiopharm
Debiopharm is a biopharmaceutical company specializing in oncology and bacterial infections.
TriSalus Life Sciences
TriSalus Life Sciences
TriSalus Life Sciences (formerly MedTech Acquisition and Surefire Medical) is a company that develops a transformative platform for treating liver and pancreatic tumors.
Sunshine Biopharma
Sunshine Biopharma
Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
Turning Point Therapeutics
Turning Point Therapeutics
Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases.
Pyxis Oncology
Pyxis Oncology
Pyxis Oncology is a preclinical oncology company focused on developing therapeutics to target difficult-to-treat cancers.
Founding Date
Founding Date
1979
Founding Date
2009
Founding Date
2006
Founding Date
2013
Founding Date
2019
Type
Type
Private
Type
Public
Type
Public
Type
Subsidiary
Type
Public
Tags
Locations
Locations
Lausanne, CH HQ
Oss, NL
Locations
Westminster, US HQ
Bannockburn, US
Cranston, US
Locations
Pointe-Claire, CA HQ
Locations
San Diego, US HQ
Locations
Cambridge, US HQ
Employees
Employees
501
Employees
106
Employees
44
Employees
57
Employees
39
Valuation ($)
Valuation ($)
N/A
Valuation ($)
117.2 m
Valuation ($)
5.8 m
Valuation ($)
N/A
Valuation ($)
227 m

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$18.5m (FY, 2023)
Revenue (est.)
$24.1m (FY, 2023)
Revenue (est.)
$30.8m (FY, 2021)
Revenue (est.)
N/A
Cost of goods
Cost of goods
N/A
Cost of goods
$2.6m (FY, 2023)
Cost of goods
$15.8m (FY, 2023)
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
$15.9m (FY, 2023)
Gross profit
$8.3m (FY, 2023)
Gross profit
N/A
Gross profit
N/A
Net income
Net income
N/A
Net income
($59m) (FY, 2023)
Net income
($4.5m) (FY, 2023)
Net income
($236.6m) (FY, 2021)
Net income
($73.8m) (FY, 2023)

Funding

Total funding raised
Total funding raised
$ 2.1m
Total funding raised
$ 52.2m
Total funding raised
N/A
Total funding raised
$ 144.4m
Total funding raised
$ 174m
For sources of this data, please see the company profile

View Company Profiles

TriSalus Life Sciences
HQ
Westminster, US
Employees
106

TriSalus Life Sciences (formerly MedTech Acquisition and Surefire Medical) is a company that develops a transformative platform for treating liver and pancreatic tumors.

View company
Sunshine Biopharma
HQ
Pointe-Claire, CA
Employees
44

Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.

View company
Turning Point Therapeutics
HQ
San Diego, US

Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases.

View company
Pyxis Oncology
HQ
Cambridge, US
Employees
39

Pyxis Oncology is a preclinical oncology company focused on developing therapeutics to target difficult-to-treat cancers.

View company